Display options
Cite
Sahakyan N, Haddad A, Richardson S, et al. Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision. Anticancer Agents Med Chem. 2017;17(8):1033-1039doi: 10.2174/1871520617666170102150730.
Sahakyan, N., Haddad, A., Richardson, S., Forcha-Etieundem, V., Christopher, L., Alharbi, H., & Campbell, R. (2017). Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision. Anti-cancer agents in medicinal chemistry, 17(8), 1033-1039. https://doi.org/10.2174/1871520617666170102150730
Sahakyan, Nare, et al. "Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision." Anti-cancer agents in medicinal chemistry vol. 17,8 (2017): 1033-1039. doi: https://doi.org/10.2174/1871520617666170102150730
Sahakyan N, Haddad A, Richardson S, Forcha-Etieundem V, Christopher L, Alharbi H, Campbell R. Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision. Anticancer Agents Med Chem. 2017;17(8):1033-1039. doi: 10.2174/1871520617666170102150730. PMID: 28042778.
Copy Download .nbib Format: NLM
Share it on

Anticancer Agents Med Chem. 2017;17(8):1033-1039. doi: 10.2174/1871520617666170102150730.

Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision.

Anti-cancer agents in medicinal chemistry

Nare Sahakyan, Amir Haddad, Shye Richardson, Valery Forcha-Etieundem, Lee Christopher, Hanan Alharbi, Robert Campbell

Affiliations

  1. Massachusetts College of Pharmacy and Health Sciences, 19 Foster St. Worcester, MA 01608, United States.
  2. Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences, 19 Foster St. Worcester, MA 01608, United States.

PMID: 28042778 DOI: 10.2174/1871520617666170102150730

Abstract

Nanotechnology has brought about the advent of personalized medicine in the era of targeted therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and summarize relevant ongoing preclinical and clinical trials.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Keywords: Personalized medicine; cancer therapy; drug delivery; nanoparticles; nanotechnology; tumor-targeted nanomedicines

MeSH terms

Publication Types